THE USE OF PROTEINASE INHIBITORS FOR PREVENTION OR REDUCTION OF BONE RESORPTION
摘要
Bone metabolic disease is treated by inhibition of the production or action of membrane-type matrix metalloproteinase (MT-MMP) or the matrix metalloproteinase 12 (MMP-12) involved in the resorptive activity of osteoclasts. Inhibitors for MT-MMP and MMP-12 and membrane-associated metalloproteinase activity include peptides and analogues of peptides generated using a PEGA bead library, antisense nucleic acid agents and antibodies. The proteinases MT1-MMP and MMP-12 are found to be expressed in osteoclasts and may be selectively inhibited.
申请公布号
WO9804287(A1)
申请公布日期
1998.02.05
申请号
WO1997EP04110
申请日期
1997.07.29
申请人
CENTER FOR CLINICAL & BASIC RESEARCH;FOGED, NIELS, TAEKKER;DELAISSE, JEAN-MARIE;MELDAL, MORTEN